Lung cancer drug combo under the microscope: Real-World data reveals all
NCT ID NCT06269133
First seen May 09, 2026 · Last updated May 23, 2026 · Updated 2 times
Summary
This study looks back at medical records of about 1,000 people with advanced non-small cell lung cancer who received a combination of the drug cemiplimab and chemotherapy. The goal is to see how safe and effective this treatment is in different groups based on age, sex, race, and ethnicity. Researchers will analyze data from US electronic health records to understand real-world outcomes like tumor response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Regeneron Research Facility
Tarrytown, New York, 10591, United States
Conditions
Explore the condition pages connected to this study.